GERMANTOWN, MD / ACCESS Newswire / July 16, 2026 / uBriGene Biosciences, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, today announced the launch of its patented uVivo™ Lentiviral Vector (LVV) Platform. uVivo™ LVV is a proven and targeted in vivo CAR-T platform that enables safer, more efficient, and commercially scalable in vivo CAR-T therapies.
CAR-T cell therapy has transformed the treatment landscape for hematologic malignancies. However, conventional autologous CAR-T manufacturing requires complex ex vivo cell collection, genetic modification, expansion, and immunodepletion, resulting in lengthy manufacturing timelines and high treatment costs.
To address these challenges, uBriGene developed the proprietary uVivo™ LVV Platform, an in vivo CAR-T technology that enables precise delivery of CAR payloads to T cells, allowing rapid generation of CAR-T cells in vivo.
"The promise of in vivo CAR-T lies in its ability to make transformative cell therapies simpler, faster, and more accessible," said Dr. Xiulian Sun, CTO and cofounder of uBriGene Biosciences. "Our uVivo™ LVV Platform combines proprietary and proven LVV engineering for precise T-cell targeting with an industry-leading manufacturing platform capable of producing thousands of doses from a single 10 L batch. By delivering both scientific innovation and manufacturing efficiency, we are helping pave the way toward safer, more affordable, and commercially viable in vivo CAR-T therapies. We are excited to make this powerful uVivo™ LVV Platform available for CAR-T therapeutic developers to catapult your CAR-T candidates into success."
